Anavex Life Sciences Corp (AVXL)

[Joseph_K]

I don't recall what clinical trials cost. $50 million for Rett isn't high?

This doesn't sound to me like a company where we need to discuss "AVXL's financial viability and the going concern concept in light of recent events":

Our cash position at December 31 was $143.8 million. During the quarter, we utilized cash and cash equivalents of $7.3 million to fund operations. At our current cash utilization rate, we believe we continue to have sufficient cash runway to fund operations and clinical programs beyond the next four years. During our most recent quarter, general and administrative expenses were $2.6 million, which is consistent with the immediately preceding fourth quarter of fiscal 2023. Our research and development expenses for the quarter were $8.7 million as compared to $10 million for the most recent fourth quarter of fiscal 2023.

Granted, there was not the expense of any trials going on that quarter, as EXCELLENCE was completed at the end of June and none had been ongoing or started since then (including 3-71 for schizophrenia, which is yet to start). OTOH, doesn't the Lincoln Park arrangement mean more money remains available (albeit with dilution)?

That was a long fallow period with no trials, and I wish 3-71 had been started much earlier (and I don't understand why it wasn't), but I don't see the company closing up shop if it doesn't get AD approval in Europe or a partner.